Articles of manufacture and methods for treatment using adoptive cell therapy

Patent metadata

Field	Value
Publication number	US-11413310-B2
Application number	US-201816616938-A
Country	US
Kind code	B2
Filing date	Jun 1, 2018
Priority date	Jun 2, 2017
Publication date	Aug 16, 2022
Grant date	Aug 16, 2022

Abstract

Provided are adoptive cell therapy methods involving the administration of doses of cells for treating disease and conditions, including certain B cell malignancies. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the methods are for treating subjects with non-Hodgkin lymphoma (NHL). In some embodiments, the methods are for treating subjects with relapsed or refractory NHL. Also provided are articles of manufacture and prophylactic treatments in connection with adoptive therapy methods.

First claim

The invention claimed is:

1. A method of treating a subject having or suspected of having a cancer, the method comprising administering to the subject a dose of CD4 + and CD8 + T cells, each of the CD4 + and the CD8 + T cells, individually, comprising a recombinant receptor that specifically binds to a target antigen expressed by the cancer or a cell or tissue thereof and/or that is associated with the cancer, wherein the administration comprises administering a plurality of separate compositions, the plurality of separate compositions comprising a first composition comprising one of the CD4 + T cells and the CD8 + T cells and a second composition comprising the other of the CD4 + T cells and the CD8 + T cells.

2. The method of claim 1 , wherein the recombinant receptor comprised by the CD4 + T cells and the recombinant receptor comprised by the CD8 + T cells comprises a recombinant receptor that is the same.

3. The method of claim 1 , wherein
the administration of the first composition and the administration of the second composition are carried out on the same day.

4. The method of claim 1 , wherein the first composition and the second composition are administered no more than 2 hours apart.

5. The method of claim 1 , wherein the first composition comprises the CD4 + T cells.

6. The method of claim 1 , wherein the first composition comprises the CD8 + T cells.

7. The method of claim 1 , wherein the initiation of the administration of the first composition is carried out prior to the initiation of the administration of the second composition.

8. The method of claim 1 , wherein the dose of CD4 + and CD8 + T cells comprises a defined ratio of CD4 + cells expressing the recombinant receptor to CD8 + cells expressing the recombinant receptor, which is between approximately 1:3 and approximately 3:1.

9. The method of claim 8 , wherein the defined ratio is approximately 1:1.

10. The method of claim 1 , wherein the dose of CD4 + and CD8 + T cells comprises between at or about 1×10 7 and at or about 2×10 8 total recombinant receptor-expressing T cells, inclusive.

11. The method of claim 1 , wherein the disease or condition is a B cell malignancy.

12. The method of claim 1 , wherein the recombinant receptor is a chimeric antigen receptor (CAR).

13. The method of claim 2 , wherein the dose of T cells comprises a defined ratio of CD4 + cells expressing the recombinant receptor to CD8 + cells expressing the recombinant receptor, which is between approximately 1:3 and approximately 3:1.

14. The method of claim 3 , wherein the dose of T cells comprises a defined ratio of CD4 + cells expressing the recombinant receptor to CD8 + cells expressing the recombinant receptor, which is between approximately 1:3 and approximately 3:1.

15. The method of claim 1 , wherein the subject is or has been identified as having an ECOG status of 0 or 1.

16. The method of claim 1 , wherein the dose of T cells comprises between at or about 5×10 7 recombinant receptor-expressing T cells and 1.5×10 8 recombinant receptor-expressing T cells, inclusive, said dose comprising a defined ratio of CD4 + cells expressing the recombinant receptor to CD8 + cells expressing the recombinant receptor, which is approximately 1:1.

17. The method of claim 1 , wherein
at or prior to administration of the dose of cells, the subject is or has been identified as having a lymphoma associated with or involving central nervous system (CNS) involvement.

18. The method of claim 2 , wherein the cancer is a B cell malignancy.

19. The method of claim 1 , wherein the cancer is a non-Hodgkin lymphoma (NHL).

20. The method of claim 1 , wherein prior to initiation of administration of the dose of cells, the subject has not been administered an agent or treatment capable of treating, preventing, delaying, reducing or attenuating the development or risk of development of a toxicity following administration of the dose of cells.

21. The method of claim 1 , wherein:
the administration and any follow up is carried out on an outpatient basis or without requiring admission to or an overnight stay at a hospital; and
if the subject exhibits a sustained fever or a fever that is or has not been reduced by more than 1° C. after treatment with an antipyretic, the subject is admitted to a hospital or to an overnight stay at a hospital, or is administered an agent or treatment for the treatment, prevention, reduction or attenuation of a neurotoxicity or a cytokine release syndrome or risk thereof.

22. The method of claim 19 , wherein the NHL is aggressive NHL.

23. The method of claim 19 , wherein, at or immediately prior to the time of the administration of the dose of cells the subject has relapsed following remission after treatment with, or become refractory to, one or more prior therapies for the NHL.

24. The method of claim 1 , wherein, at or prior to the administration of the dose of cells:
the subject is or has been identified as having a double/triple hit lymphoma;
the subject is or has been identified as having a chemorefractory lymphoma;
the subject has not achieved complete remission (CR) in response to a prior therapy; or
the subject has relapsed within 1 year or less than 1 year after receiving an autologous stem cell transplant (ASCT).

25. The method of claim 12 , wherein
the CAR comprises an scFv specific for CD19, a transmembrane domain, a cytoplasmic signaling domain derived from a costimulatory molecule, a cytoplasmic signaling domain that comprises a CD3zeta signaling domain, and a spacer between the transmembrane domain and the scFv.

26. The method of claim 1 , wherein, prior to the administration, the subject has been preconditioned with a lymphodepleting therapy comprising the administration of fludarabine, cyclophosphamide, or fludarabine and cyclophosphamide.

27. The method of claim 2 , wherein
the first composition and second composition are administered 0 to 12 hours apart.

28. The method of claim 2 , wherein the first composition and second composition are administered no more than 2 hours apart.

29. The method of claim 6 , wherein the first composition is administered prior to the second composition.

30. The method of claim 2 , wherein the first composition comprises the CD8 + T cells.

31. The method of claim 30 , wherein the first composition is administered prior to the second composition.

32. The method of claim 25 , wherein the costimulatory molecule is or comprises a 4-1BB.

33. The method of claim 25 , wherein the spacer consists of all or a portion of an immunoglobulin hinge and is 15 amino acids or fewer in length.

34. The method of claim 33 , wherein the spacer is at or about 12 amino acids in length.

35. The method of claim 25 , wherein the spacer consists of the sequence of SEQ ID NO: 1.

36. The method of claim 25 , wherein the scFv comprises a CDRL1 sequence of RASQDISKYLN (SEQ ID NO: 35), a CDRL2 sequence of SRLHSGV (SEQ ID NO: 36), a CDRL3 sequence of GNTLPYTFG (SEQ ID NO: 37); a CDRH1 sequence of DYGVS (SEQ ID NO: 38), a CDRH2 sequence of VIWGSETTYYNSALKS (SEQ ID NO: 39), and a CDRH3 sequence of YAMDYWG (SEQ ID NO: 40).

37. The method of claim 25 , wherein the scFv comprises the V

Assignees

• Juno Therapeutics Inc

Inventors

• Albertson Tina
• Christin Brian
• Garcia Jacob Randolph
• Ramsborg Christopher Glen
• Sutherland Claire L
• Weber Clinton
• Yost Rachel K
• Gilbert Mark J
• Li He

Classifications

• A61K40/4211

  CD19 or B4 · CPC title

• A61K40/31

  Chimeric antigen receptors [CAR] · CPC title

• A61K40/11

  T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells · CPC title

• A61K2239/38

  characterised by the dose, timing or administration schedule · CPC title

• A61K2039/545

  characterised by the dose, timing or administration schedule · CPC title